IRIS
GATTO, FEDERICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 8.314
AS - Asia 1.045
NA - Nord America 575
SA - Sud America 96
AF - Africa 17
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 10.049
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 8.109
US - Stati Uniti d'America 544
SG - Singapore 453
CN - Cina 267
VN - Vietnam 209
FR - Francia 76
BR - Brasile 70
FI - Finlandia 45
HK - Hong Kong 40
DE - Germania 23
GB - Regno Unito 21
IQ - Iraq 14
MX - Messico 12
CA - Canada 11
AR - Argentina 10
IE - Irlanda 10
JP - Giappone 10
ID - Indonesia 8
PH - Filippine 8
BD - Bangladesh 7
ZA - Sudafrica 6
IN - India 5
RU - Federazione Russa 5
VE - Venezuela 5
CH - Svizzera 4
CO - Colombia 4
AE - Emirati Arabi Uniti 3
MA - Marocco 3
TH - Thailandia 3
TR - Turchia 3
UA - Ucraina 3
AZ - Azerbaigian 2
BY - Bielorussia 2
CL - Cile 2
DZ - Algeria 2
EC - Ecuador 2
ES - Italia 2
KZ - Kazakistan 2
NL - Olanda 2
NP - Nepal 2
SE - Svezia 2
AL - Albania 1
AT - Austria 1
AU - Australia 1
BE - Belgio 1
BG - Bulgaria 1
BO - Bolivia 1
BZ - Belize 1
CR - Costa Rica 1
CW - ???statistics.table.value.countryCode.CW??? 1
DJ - Gibuti 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GA - Gabon 1
HN - Honduras 1
HR - Croazia 1
IL - Israele 1
JO - Giordania 1
KE - Kenya 1
LT - Lituania 1
MM - Myanmar 1
MQ - Martinica 1
MU - Mauritius 1
NE - Niger 1
NG - Nigeria 1
NI - Nicaragua 1
OM - Oman 1
PE - Perù 1
PK - Pakistan 1
PR - Porto Rico 1
PS - Palestinian Territory 1
PT - Portogallo 1
PY - Paraguay 1
RO - Romania 1
SA - Arabia Saudita 1
SI - Slovenia 1
TW - Taiwan 1
UZ - Uzbekistan 1
VI - Stati Uniti Isole Vergini 1
Totale 10.049
Salva come PNG Salva come JPEG
Città #
Genova 3.923
Genoa 2.743
Vado Ligure 821
Rapallo 520
Singapore 211
San Jose 202
Lauterbourg 68
Council Bluffs 67
Ashburn 64
Ho Chi Minh City 55
Hanoi 50
Beijing 38
Hong Kong 36
Helsinki 33
New York 24
Santa Clara 22
Frankfurt am Main 17
Haiphong 14
Lappeenranta 12
Rome 11
Bordighera 10
St Louis 10
Tokyo 10
Milan 9
Orem 9
Da Nang 8
Dublin 8
London 8
Los Angeles 8
Turin 8
Mexico City 7
Biên Hòa 6
São Paulo 6
Can Tho 5
Johannesburg 5
Montreal 5
Baghdad 4
Chicago 4
City of London 4
Des Moines 4
Hải Dương 4
Ninh Bình 4
Reggio Emilia 4
Thái Nguyên 4
Tianjin 4
Zurich 4
Miami 3
Piscataway 3
San Juan 3
Schiffdorf 3
Shanghai 3
Todi 3
Baku 2
Bangkok 2
Bogotá 2
Bologna 2
Buenos Aires 2
Cardiff 2
Changsha 2
Charlotte 2
Curitiba 2
Detroit 2
Erbil 2
Fayetteville 2
Fort Lauderdale 2
Guangzhou 2
Ha Long 2
Imus 2
Ipatinga 2
Lastra a Signa 2
Maceió 2
Marseille 2
Milwaukee 2
Modena 2
Montes Claros 2
Mosul 2
Palermo 2
Phủ Lý 2
Pisa 2
Poplar 2
Porto Alegre 2
Quận Ba 2
Salt Lake City 2
San Lazzaro di Savena 2
Surabaya 2
The Dalles 2
Vũng Tàu 2
Điện Bàn 2
Abha 1
Acalanes Ridge 1
Ajman 1
Alençon 1
Almaty 1
Amman 1
Amsterdam 1
Anand 1
Andaraí 1
Ankara 1
Apopka 1
Araure 1
Totale 9.195
Salva come PNG Salva come JPEG
Nome #
Clinical outcome and evidence of high rate post-surgical anterior hypopituitarism in a cohort of TSH-secreting adenoma patients: Might somatostatin analogs have a role as first-line therapy? 214
Conventional and nuclear medicine imaging in Ectopic Cushing's syndrome: A systematic review 213
SOMATOSTATIN AND DOPAMINE RECEPTOR INTERACTION IN PROSTATE AND LUNG CANCER CELL LINES 209
Diabetes secondary to neuroendocrine gastroenteropancreatic tumors 208
Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells 200
The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology 188
Phenotypical and Pharmacological Characterization of Stem-Like Cells in Human Pituitary Adenomas 187
Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogs and dopastatins 179
Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: effect of mono- and bi-specific somatostatin analogs on cell growth. 178
Emerging targets in pituitary adenomas: role of the CXCL12/CXCR4-R7 system 177
Dipeptidyl peptidase-4 inhibitors do not alter GH/IGF-I axis in adult diabetic patients 177
Hormone receptors analysis in idiopathic progressive subglottic stenosis 175
Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms 175
Patient-derived xenograft in zebrafish embryos: a new platform for translational research in neuroendocrine tumors 168
Case report: Twice-daily tolvaptan dosing regimen in a challenging case of hyponatremia due to SIAD 162
Aggressive and malignant prolactinomas 162
Somatostatin receptor scintigraphy in thoracic diseases 155
Immunoreactivity Score Using an Anti-sst2A Receptor Monoclonal Antibody Strongly Predicts the Biochemical Response to Adjuvant Treatment with Somatostatin Analogs in Acromegaly 151
Somatostatin receptor ligands in the treatment of acromegaly 151
Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly 151
Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center 149
Does pasireotide directly modulate skeletal muscle metabolism? 149
Octreotide and pasireotide combination treatment in somatotroph tumor cells: Predominant role of sst2 in mediating ligand effects 149
Role of dopamine receptors in normal and tumoral pituitary corticotropic cells and adrenal cells 146
Epidemiology of acromegaly in Italy: analysis from a large longitudinal primary care database 145
P68 Insulin-like growth factor (IGF) binding protein-3 inhibits IGF-II-stimulated IRS-1/PI-3-kinase activity and cell growth in human non-small cell lung cancer (NSCLC) cell lines 144
OR2,6 Interrelationship between somatostatin/dopamine pathways and growth factors in non-small lung cancer cells 142
Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly 142
Emerging drugs for the treatment of acromegaly 141
Clinical and radiological presentation of parasellar ectopic pituitary adenomas: case series and systematic review of the literature 139
Diagnosis and Treatment of Parasellar Lesions 139
In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5 136
P87 Effect of exenatide, sitagliptin and vildagliptin on IGF-I in diabetic patients 134
Regulation Of Prostate Cancer Cell Proliferation By Somatostatin Receptor Activation 132
In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas 130
Pre-surgical treatment with somatostatin analogues in patients with acromegaly: The case for 129
Abstracts of the 6th Annual ENETS Conference, Granada, Spain, March 5–7, 2009 129
Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives 129
Immunohistochemical localization and quantitative expression of somatostatin receptors in normal human spleen and thymus: implications for the in vivo visualization during somatostatin receptor scintigraphy. 128
The role of somatostatin and dopamine D2 receptors in endocrine tumors 128
Novel chimeric somatostatin analogs: facts and perspectives 125
Extraintestinal precoccygeal tumour with endocrine features and its relationship with Currarino syndrome. 120
Body Composition and Bone Status in Relation to Microvascular Damage in Systemic Sclerosis Patients 120
PD-L1 expression, BRAF and TERT mutation in a cohort of aggressive thyroid cancers: case series from a single-centre experience 118
Modulatory activity of testosterone on growth pattern and IGF-1 levels in vanishing testis syndrome: a case report during 15 years of follow-up 114
Clinical and Radiological Predictors of Biochemical Response to First-Line Treatment With Somatostatin Receptor Ligands in Acromegaly: A Real-Life Perspective 113
null 110
null 110
Temporal and masseter muscle evaluation by MRI provides information on muscle mass and quality in acromegaly patients 109
Hyperthyroidism in non-seminomatous testicular germ cell tumors: two case reports and literature review 109
null 109
An unusual cause of adrenal insufficiency with elevation of 17-hydroxyprogesterone: case report 107
Discordant GH and IGF-1 Results in Treated Acromegaly: Impact of GH Cutoffs and Mean Values Assessment 107
null 104
Novel Molecular Mechanisms of Resistance to Somatostatin Analog Treatment in Pituitary Adenomas 103
Ultra-short antibiotic prophylaxis guided by preoperative microbiological nasal swabs in endoscopic endonasal skull base surgery 98
The effect of sodium restriction on iodine prophylaxis: a review 94
Differential Impact of Medical Therapies for Acromegaly on Glucose Metabolism 92
GH Replacement in the Elderly: Is It Worth It? 92
Challenging diagnosis of resistance to thyroid hormone in a patient with COVID-19, pituitary microadenoma and unusual response to octreotide long-acting release test 87
Acromegaly Management in a Tertiary Referral Center After 1 Year of the Coronavirus 2019 Pandemic: A Double Challenge 77
Sodium Intake and Target Organ Damage in Hypertension-An Update about the Role of a Real Villain 77
Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients 73
Somatostatin receptors and the associated intracellular machinery: the two sides of the coin 72
Dissecting the in vitro efficacy of octreotide and cabergoline in GH- and GH/PRL-secreting pituitary tumors 72
Corrigendum to "Regulation of prostate cancer cell proliferation by somatostatin receptor activation" [Mol. Cell. Endocrinol. 315 (1-2) (2010) 254-262] 70
Trabecular Bone Score as a Reliable Measure of Lumbar Spine Bone Microarchitecture in Acromegalic Patients 68
Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression 68
Pasireotide effects on biochemical control and glycometabolic profile in acromegaly patients switched from combination therapies or unconventional dosages of somatostatin analogs 67
Cemiplimab and diabetic ketoacidosis: a case report of a rare endocrinopathy associated with immune checkpoint inhibitors 67
Digital quantification of somatostatin receptor subtype 2a immunostaining: a validation study 66
Left ventricular mass reduction by a low-sodium diet in treated hypertensive patients 64
Baseline testosterone levels as a predictor of hypogonadism resolution in male patients with isolated hyperprolactinemia 62
null 61
Diabetes mellitus in patients with acromegaly: pathophysiology, clinical challenges and management 59
Digital quantification of somatostatin receptor subtypes 2 and 5 in growth hormone–secreting pituitary tumors 58
β-arrestin expression in corticotroph tumor cells is modulated by glucocorticoids 58
Off-label pasireotide treatment in one insulinoma patient with an atypical presentation and intolerant to diazoxide 55
Cushing's syndrome 55
Evaluation of acromegaly treatment direct costs with respect to biochemical control and follow-up length 52
Treatment of Acromegalic Osteopathy in Real-life Clinical Practice: The BAAC (Bone Active Drugs in Acromegaly) Study. 50
Skeletal Muscle Evaluation in Patients With Acromegaly 49
Somatostatin receptor expression and patients' response to targeted medical treatment in pituitary tumors: evidences and controversies. 48
The paradoxical GH response at OGTT does not predict Pasireotide efficacy but matters for glucose metabolism 43
Editorial: Resistance to Medical Therapy in Pituitary Tumors 39
Octreotide Subcutaneous Depot for Acromegaly: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial, ACROINNOVA 1 34
Octreotide-resistant acromegaly: Challenges and solutions 29
Routine Evaluation of Somatostatin Receptor Type 2 in Patients With Acromegaly: Do We Still Need More Evidence? 29
null 28
La composizione dei macronutrienti nella dieta influenza l’asse somatotropo: un potenziale trattamento per l’acromegalia? 26
Current clinical practice for thromboprophylaxis management in patients with Cushing's syndrome across reference centers of the European Reference Network on Rare Endocrine Conditions (Endo-ERN) 26
Venous thromboembolism in Cushing syndrome: results from an EuRRECa and Endo-ERN survey 24
Somatostatin receptor pathophysiology in the neuroendocrine system 22
European survey on metabolic and cardiovascular risk in Cushing syndrome 19
Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant 19
Impact of Nutrition on Somatotroph Axis: A Potential Role in Acromegaly and Its Cardiovascular Risk? 17
β-Arrestin 1 and 2 and G protein-coupled receptor kinase 2 expression in pituitary adenomas: role in the regulation of response to somatostatin analogue treatment in patients with acromegaly. 16
Global epidemiology of acromegaly: a systematic review and meta-analysis 16
Gender differences in the glycometabolic and cardiovascular features of acromegaly 14
Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists. 12
Totale 10.342
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.224
article - articoli 32.395
book - libri 278
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 551
Totale 66.448
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021175 0 0 0 0 0 0 0 0 0 83 57 35
2021/2022709 16 14 80 95 26 56 26 166 51 61 26 92
2022/2023641 56 62 5 47 68 105 18 41 118 11 98 12
2023/2024502 25 54 10 61 29 87 42 24 27 39 37 67
2024/20251.994 71 131 59 146 263 219 191 316 73 84 201 240
2025/20263.152 405 86 348 337 414 289 488 156 303 326 0 0
Totale 10.352